Latest Articles

Publication Date
Fallopian tube cavernous haemangioma found during the caesarean section of a woman with a history of endometriosis: a case report and literature review.

This case report describes the management of fallopian tube cavernous haemangioma discovered at caesarean section, and provides insight to the literature on this extremely rare benign vascular tumor with regard …

Published: Oct. 28, 2025, midnight
Bayer’s New Study on Mirena: A Potential Game-Changer for Endometrial Hyperplasia Treatment - TipRanks

Bayer’s New Study on Mirena: A Potential Game-Changer for Endometrial Hyperplasia Treatment TipRanks

Published: Oct. 27, 2025, 11:58 p.m.
Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 11:43 p.m.
BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 10:53 p.m.
Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic - citybuzz -

Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic citybuzz -

Published: Oct. 27, 2025, 9:33 p.m.
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks

Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 9:13 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 27, 2025, 7:50 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Yahoo Finance

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Yahoo Finance

Published: Oct. 27, 2025, 7:33 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 27, 2025, 7:33 p.m.
Aspira Women’s Health Advances Endometriosis Diagnosis with EndoCheck Study - TipRanks

Aspira Women’s Health Advances Endometriosis Diagnosis with EndoCheck Study TipRanks

Published: Oct. 27, 2025, 6:47 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!